CelLBxHealth’s Parsortix® system has been shown to successfully isolate Glioblastoma (GBM) circulating tumor cells (CTCs) and CTC clusters from patient blood samples for downstream molecular analysis. Our service and R&D laboratories provide genetic profiling of CTCs to potentially aid in classifying GBM subtypes (BRAF, IDH 1/2, Anti-MET, EGFR, etc.) for targeted patient selection into clinical trials and longitudinal monitoring.
Secure your 1:1 appointment below and learn more about:
Location
Honolulu, Hawaii, USA
Date
November 19-23, 2025
CelLBxHealth attendees
Request a meeting with the CelLBxHealth team at the WFNOS/SNO
Brett Swansiger
Chief Commercial Officer
Brett plays a key role in our global corporate partnerships and overseeing our commercial teams in their biopharma services activities and research/clinical product solutions. Brett has over 20 years of commercial leadership, international business development, and business to business sales.
Brett Swansiger
Chief Commercial Officer
Brett plays a key role in our global corporate partnerships and overseeing our commercial teams in their biopharma services activities and research/clinical product solutions. Brett has over 20 years of commercial leadership, international business development, and business to business sales.